Tollen v. Geron Corporation

District Court, N.D. California·Decided April 2, 2022·No. 3:20-cv-00547·Unknown

Opinion

NORTHERN DISTRICT OF CALIFORNIA JULIA JUNGE and RICHARD JUNGE, on behalf of themselves and similarly situated investors, No. C 20-00547-WHA Plaintiffs, v. ORDER RE MOTION TO CERTIFY CLASS, APPOINT CLASS GERON CORPORATION and REPRESENTATIVES, AND JOHN A. SCARLETT, APPOINT CLASS COUNSEL Defendants. INTRODUCTION In this PSLRA securities action, lead plaintiffs move to certify a class. They also move for appointment as class representatives and for appointment of lead counsel. To the extent stated below, the motion is GRANTED. A prior order detailed the facts of the operative complaint (Dkt. Nos. 103, 124). In brief, court-appointed lead plaintiffs Julia and Richard Junge invested in defendant Geron Corporation. At all material times, defendants Geron and its President and CEO John A. Scarlett worked to develop a single drug, imetelstat. Defendants hoped that imetelstat could improve quality of life and/or survival for patients with myelofibrosis, a cancer affecting bone marrow (Amd. Compl. ¶¶ 51, 52). The putative class period (March 19, 2018, through September 26, 2018) covered the late stages of Geron’s phase-two clinical trial, which was titled IMbark. To conduct the trial, Geron partnered with Janssen Biotech Inc. The companies sought to measure whether imetelstat could improve certain health markers, known as study “endpoints.” Three of the endpoints were total symptom score (TSS), complete and/or partial remission (CR/PR), and spleen volume reduction (SVR). Our prior order granted in part defendants’ motion to dismiss but let claims proceed as to certain categories of statements (Dkt. No. 124 at 9–11). Specifically, Geron and Scarlett allegedly warmed the market on Geron common stock by issuing optimistic statements about IMbark’s TSS and CR/PR endpoints, when really the data disappointed. As alleged, the first disclosure occurred March 19, 2018, whereupon it artificially inflated the price of Geron common stock. Numerous other disclosures, too, allegedly inflated stock prices throughout the class period. The truth eventually came out, per the complaint. Geron revealed TSS and CR/PR data after the market closed on September 26, 2018. Before the market opened the next day, Janssen announced it would quit the partnership with Geron. These two disclosures therefore shared the same “market date” of September 27 (Campisi Decl. Exh. A, n. 67, Exh. 7). Over the two days that followed, Geron stock price plunged by approximately 70% (ibid.; Amd. Compl. ¶¶ 14, 41). Lead plaintiffs now move to certify a class under FRCP 23(a) and 23(b)(3) consisting of:

All persons who purchased Geron common stock during the period from March 19, 2018, to September 26, 2018, inclusive, and who were damaged thereby (the “Class”).1 In support of this motion, lead plaintiffs submit an expert report by Chad Coffman, CFA, and copies of SEC filings that contain some of the alleged misrepresentations. They also move to appoint plaintiffs Julia and Richard Junge as class representatives and to appoint Kaplan Fox as class counsel. Defendants oppose certification, arguing that predominance is not met as to damages. This order follows full briefing and oral argument (Dkt. No. 141, Campisi Decl. ¶¶ 3, 4). Certification under Rule 23(b)(3) is a two-step process. A plaintiff must first show that the four prerequisites of Rule 23(a) are met: (1) the class is so numerous that joinder of all members is impracticable; (2) questions of law or fact exist common to the class; (3) the claims or defenses of the representative parties are typical of the claims or defenses of the class; and (4) the representative parties will fairly and adequately protect the interests of the class. For a damages class under Rule 23(b)(3), a plaintiff must establish “that the questions of law or fact common to class members predominate over any questions affecting only individual members, and that a class action is superior to other available methods for fairly and efficiently adjudicating the controversy.” A plaintiff bears the burden of demonstrating that these requirements are met. See Abdullah v. U.S. Sec. Assocs., Inc., 731 F.3d 952, 956–57 (9th Cir. 2013). The Supreme Court has “cautioned that a court’s class-certification analysis must be rigorous and may entail some overlap with the merits of the plaintiff’s underlying claim,” Wal– Mart Stores, Inc. v. Dukes, 564 U.S. 338, 350 (2011) (cleaned up); however, “[m]erits questions may be considered to the extent — but only to the extent — that they are relevant to determining whether the Rule 23 prerequisites for class certification are satisfied.” Amgen Inc. v. Conn. Ret. Plans and Tr. Funds, 568 U.S. 455, 464–65 (2013). Defendants oppose class certification because, they argue, plaintiffs have failed to propose a viable class-wide damages model. This order examines each requirement of the class certification analysis to ensure that the putative class satisfies the requirements of Rule 1. RULE 23(a). A. NUMEROSITY. At all material times, Geron common stock was registered and traded on the NASDAQ stock exchange, with more than 173 million shares outstanding; defendants admit that Geron sold over ten million shares during the class period; and a FINRA registered broker sold Geron stock to at least 100 unique account holders during the class period (Campisi Decl. Exh. A ¶¶ 26–30, 67; Exh. B at 13–15). Thus, “[j]oinder of all members is impracticable.” FRCP 23(a). B. COMMONALITY. To show commonality, a plaintiff “need not show . . . that every question in the case, or even a preponderance of questions, is capable of class wide resolution. So long as there is even a single common question, a would-be class can satisfy the commonality requirement of Rule 23(a)(2).” Parsons v. Ryan, 754 F.3d 657, 675 (9th Cir. 2014) (cleaned up). Here, plaintiffs’ allegations that the same public misrepresentations in Securities and Exchange Commission (SEC) filings and earnings calls defrauded investors and that the investors suffered similar losses as a result fulfill Rule 23(a)’s commonality requirement. Even if individual damages calculations ultimately will differ, it appears that the artificial inflation per share (if any) will be the same for each class member. C. TYPICALITY. Typicality suffices if “the claims or defenses of the representative parties are typical of the claims or defenses of the class.” FRCP 23(a)(3). “Under the rule’s permissive standards, representative claims are ‘typical’ if they are reasonably co-extensive with those of absent class members; they need not be substantially identical.” Hanlon v. Chrysler Corp., 150 F.3d 1011, 1020 (9th Cir. 1998). A district court cannot, however, certify a class if a putative class representative is subject to “unique defenses which threaten to become the focus of the litigation.” Hanon v. Dataproducts Corp., 976 F.2d 497, 508 (9th Cir. 1992). In the instant action, the surviving alleged misrepresentations and subsequent disclosures caused the Junges, and absent class members alike, to suffer financial loss. The Junges’ claims rest on the same legal theories as the claims of absent class members, so the Junges appear typical. D. ADEQUACY. The adequacy requirement of Rule 23(a)(4) permits certification only if “the representative parties will fairly and adequately protect the interests of the class.” The two key inquiries are (1) whether

Free access — add to your briefcase to read the full text and ask questions with AI

Tollen v. Geron Corporation, (N.D. Cal. 2022).

Tollen v. Geron Corporation (Tollen v. Geron Corporation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Affiliated Ute Citizens of Utah v. United States
406 U.S. 128 (Supreme Court, 1972)
Basic Inc. v. Levinson
485 U.S. 224 (Supreme Court, 1988)
Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
Wolin v. Jaguar Land Rover North America, LLC
617 F.3d 1168 (Ninth Circuit, 2010)
Schleicher v. Wendt
618 F.3d 679 (Seventh Circuit, 2010)
Wal-Mart Stores, Inc. v. Dukes
131 S. Ct. 2541 (Supreme Court, 2011)
Ellis v. Costco Wholesale Corp.
657 F.3d 970 (Ninth Circuit, 2011)
Cammer v. Bloom
711 F. Supp. 1264 (D. New Jersey, 1989)
Victor Parsons v. Charles Ryan
754 F.3d 657 (Ninth Circuit, 2014)
Muhammed Abdullah v. U.S. Security Associates, Inc.
731 F.3d 952 (Ninth Circuit, 2013)
Howard v. Liquidity Services, Inc.
322 F.R.D. 103 (District of Columbia, 2017)
Lentell v. Merrill Lynch & Co.
396 F.3d 161 (Second Circuit, 2005)
Krogman v. Sterritt
202 F.R.D. 467 (N.D. Texas, 2001)
In re Diamond Foods, Inc., Securities Litigation
295 F.R.D. 240 (N.D. California, 2013)
In re Barrick Gold Securities Litigation
314 F.R.D. 91 (S.D. New York, 2016)